<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433458</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2101</org_study_id>
    <secondary_id>2011-001596-39</secondary_id>
    <nct_id>NCT01433458</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects</brief_title>
  <official_title>A Single-dose, Open-label Parallel Study to Assess the Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of RLX030 during and after administration in&#xD;
      subjects with mild to severe hepatic impairment and matched healthy control subjects.&#xD;
&#xD;
      20 to 24 patients and 20 to 24 healthy subjects will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration at 24 hour (C24h) after administration</measure>
    <time_frame>Upto Day 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>Day 15</time_frame>
    <description>Monitoring of adverse events, serious adverse events and death from screening to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the presence and quantification of anti-RLX030 antibodies</measure>
    <time_frame>Day 1 (prior to administration) and Day 15 end of study</time_frame>
    <description>Blood will be collected and serum analyzed for the presence of antiRLX030 antibodies. Anti-RLX030 antibodies will be evaluated in serum in a validated four-tiered assay approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time [MRT] of RLX030</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life (T ½) of RLX030</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance of RLX030 from serum (CL)</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>RLX030: Group 1 mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLX030: Group 2 moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLX030: Group 3 severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLX030: Group 4 - healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLX030A</intervention_name>
    <description>RLX030 is administered as a continuous 24 hour infusion</description>
    <arm_group_label>RLX030: Group 1 mild hepatic impairment</arm_group_label>
    <arm_group_label>RLX030: Group 2 moderate hepatic impairment</arm_group_label>
    <arm_group_label>RLX030: Group 3 severe hepatic impairment</arm_group_label>
    <arm_group_label>RLX030: Group 4 - healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  All subjects:&#xD;
&#xD;
             • Female subjects must be of non-child bearing potential OR use an effective method of&#xD;
             contraception and sexually active males must use a condom during intercourse while&#xD;
             taking the drug and for 5 half-lives after stopping treatment&#xD;
&#xD;
          -  Subjects with hepatic impairment:&#xD;
&#xD;
               -  Subjects must have either mild, moderate or severe hepatic impairment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  All subjects&#xD;
&#xD;
               -  Hepatic impairment due to non-liver disease&#xD;
&#xD;
               -  Use of other investigational drugs at time of enrollment&#xD;
&#xD;
               -  History of malignancy of any organ system&#xD;
&#xD;
               -  Donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to&#xD;
                  initial dosing&#xD;
&#xD;
               -  Hemoglobin levels below 10.0 g/dL at screening or baseline&#xD;
&#xD;
          -  Subjects with hepatic impairment:&#xD;
&#xD;
               -  Presence of any non-controlled and clinically significant disease that could&#xD;
                  affect the study outcome or that would place the patient at undue risk&#xD;
&#xD;
               -  Treatment with any cytostatic drug, vasodilator, autonomic alpha blocker or B2&#xD;
                  agonist&#xD;
&#xD;
               -  Any surgical or medical condition other than hepatic impairment which might&#xD;
                  significantly alter the distribution or excretion of drugs&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grunstadt</city>
        <zip>D-67269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115419</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7565</url>
    <description>Results for CRLX030A2101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>RLX030</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

